Making Oncology History: Imatinib Pioneer Created His Own Opportunities

Beth Fand Incollingo @fandincollingo
Published: Thursday, Jan 17, 2013
Dr. Brian J. Druker Brian J. Druker, MD
There are lessons to be learned from interacting with cancer patients, and⎯luckily for the oncology community⎯Brian J. Druker almost missed the most important one.

“Because of what I did and the sacrifices I made,” the 57-year-old said, “I got to see patients who benefited from a treatment I helped develop, and got to give them hope when they had no hope. That’s a gift that can’t be replaced by anything else.”

Continuing the Fight

In the years since imatinib’s approval, Druker has maintained his focus on finding new and better treatments for CML and other leukemias. In particular, he’s seeking ways to beat the resistance to imatinib that arises in about 15% of patients with CML within five years of beginning treatment.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication